Efficacy of Trimetazidine Dihydrochloride for Relieving Chronic Tinnitus: A Randomized Double-Blind Study.
- Author:
Tolgar Lütfi KUMRAL
1
;
Güven YILDIRIM
;
Güler BERKITEN
;
Ziya SALTÜRK
;
Enes ATAÇ
;
Yavuz ATAR
;
Yavuz UYAR
Author Information
- Publication Type:Randomized Controlled Trial ; Original Article
- Keywords: Tinnitus; Trimetazidine Dihydrochloride; Drug Treatment
- MeSH: Double-Blind Method*; Hearing; Humans; Prospective Studies; Tinnitus*; Trimetazidine*
- From:Clinical and Experimental Otorhinolaryngology 2016;9(3):192-197
- CountryRepublic of Korea
- Language:English
- Abstract: OBJECTIVES: To evaluate the efficacy of trimetazidine dihydrochloride as a treatment for chronic tinnitus. METHODS: A total of 97 chronic tinnitus patients were evaluated in this randomized, prospective, double-blind, placebo-controlled trial. After assessing for eligibility, 82 patients were randomly assigned into placebo or trimetazidine groups according to the medication. The trimetazidine group received 20×3 mg/day per oral trimetazidine dihydrochloride and the placebo group received 20×3 mg/day per oral placebo for 3 months. Tinnitus handicap inventory (THI), visual analogue scale (VAS) questionnaires and audiometric results were used to determine the effectiveness of trimetazidine treatment. RESULTS: The study group comprised 82 tinnitus subjects, 42 (51%) of whom received trimetazidine dihydrochloride and 40 (49%) who received placebo. There was no significant difference between placebo and trimetazidine groups in THI grade and VAS (both pre- and posttreatment scores) (P>0.05) and no significant improvement was observed in subjective loudness score in either group (P>0.05). Additionally there was no significant difference between groups in pre- and posttreatment pure tone hearing thresholds at all measured frequencies (P>0.05). CONCLUSION: Trimetazidine dihydrochloride therapy was ineffective for relieving chronic tinnitus.
